Introduction
Patients who are systemically immunosuppressed, either pathologically or iatrogenically, can show inferior responses to radiotherapy [1] . In addition, locoregionally delivered radiotherapy can trigger tumour responses outside the radiation field that are, at least in part, immunologically mediated [2] . These observations suggest an important link between clinical responses to radiotherapy and the immune system. Until recently, it was widely believed that the cytotoxicity of radiotherapy was entirely tumour cell-autonomous and mediated by radiation-induced DNA damage (RIDD). According to this model, inflicting breaks in nuclear DNA above an unspecified threshold that the cell is incapable of repairing would lead to cell death, typically via apoptosis or mitotic catastrophe [3] . Latterly, non-tumour cell-autonomous, immunological aspects of radiation-induced cell death have been seen as increasingly important, alongside a greater understanding of the profound effects of radiotherapy on the wider tumour microenvironment.
Radiotherapy has both immunostimulatory and immunosuppressive effects [4] . The balance between these two effects depends on the intrinsic biology of individual tumours and their associated microenvironments, as well as the physical characteristics of the delivered radiation. A central component of this balance is the relationship between the RIDD response and the subsequent immune reaction. Radiotherapy can induce immunogenic cell death, characterised by tumour cell surface expression of calreticulin and release of danger-associated molecular patterns (DAMPs), including ATP and high-mobility group protein B1 [5] . Conserved antiviral pathways that detect foreign nucleic acid in the cytosol and drive downstream Immunological consequences of RIDD 607 interferon (IFN) responses are key components of the immune response to radiotherapy. This review will discuss our current understanding of the immunological consequences of RIDD, with particular focus on the role of conserved IFN responses. Although the review focuses on RIDD, the immunological consequences of DNA damage that we describe are of relevance beyond radiotherapy. We will also discuss some of the key effects of radiotherapy on components of the tumour microenvironment.
RIDD can drive production of type 1 IFN and a subsequent antitumour CD8+ T cell response
Preclinical work has demonstrated that the efficacy of radiotherapy in immunocompetent melanoma murine models relies upon induction of type 1 IFNs, which stimulate both innate and adaptive antitumour immune responses [6] . Ablative radiotherapy increased intratumoural IFN-β and the therapeutic efficacy of radiotherapy was abrogated in mice lacking the IFN-α/β receptor 1. Tumour-infiltrating CD45+ haematopoietic cells (predominantly dendritic cells) were the main source of the type 1 IFN. Subsequent tumour rejection required CD8+ T cells, and the associated expansion of antigen-specific CD8+ T cells was driven by IFN-β.
Further work has shown that the acute induction of type 1 IFN following radiotherapy is predominantly driven by cytosolic double-stranded DNA (dsDNA) that arises as a consequence of RIDD [7] . Cytosolic dsDNA is 'sensed' by the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS), which increases levels of the downstream adaptor stimulator of IFN genes (STING). STING drives increased production of type 1 IFN, which leads to activation of BATF3+ dendritic cells and subsequent priming of tumour-specific CD8+ T cells [6, 7] , as shown in Figure 1 .
Although antigen-presenting cells, such as conventional dendritic cells, are probably the main source of type 1 IFN, intrinsic cancer cell production has also been demonstrated [8] . In vitro irradiation of TSA1 and 4T1 mouse breast cancer cells and MCA38 mouse colorectal cancer cells, in the absence of stroma, showed that generation of IFN-stimulated gene (ISG) products can be a tumour cell-autonomous response independent of antigen-presenting cells. In addition, delivery of cytosolic DNA from irradiated tumour cells to antigen-presenting cells via exosomes has also recently been reported [9] . This study specifically identified dsDNA within the exosome, as opposed to dsDNA on its external surface, as the key factor inducing downstream IFN production. Furthermore, exosomes derived from tumours treated with radiotherapy were able to induce protective antitumour immunity when injected subcutaneously as a vaccination strategy. This immune response included induction of tumour-specific T cells, demonstrating the potent immunogenicity of such exosomes. Radiation-induced acute production of type 1 IFN. Following tumour cell irradiation, dsDNA is present in the cytosol where it can stimulate the dsDNA sensor cGAS and the downstream STING pathway (1) . Exosomal transfer of dsDNA to antigen-presenting cells can also occur leading to cGAS/STING pathway signalling within the antigen-presenting cell (2) . Micronuclei arising in the daughter cells of irradiated tumour cells can also release dsDNA, which stimulates cGAS and drives signalling via STING (3) . Increased signalling via the cGAS/STING pathway leads to activation of BATF3+ dendritic cells and subsequent priming of tumour-specific T cells.
Micronuclei arising from cell cycle progression through mitosis in cells harbouring double-strand breaks, for example following radiotherapy, can also drive acute production of type 1 IFNs via the cGAS/STING pathway [10] . This alternative mechanism of acute IFN production was elucidated by identification of a biphasic DNA damage-induced inflammatory response in irradiated cells. This included a delayed-onset response occurring days after DNA damage, alongside the rapid response occurring within minutes to hours discussed earlier. In irradiated MCF1A cells, and following disruption of the micronuclear envelope, cGAS localised to micronuclei post-mitosis. Robust activation of ISGs (e.g. STAT1) followed, although this effect was lost if mitotic progression was blocked, or if cGAS or STING were knocked down. An independent set of experiments validated the above mechanism: at 6 days after irradiation at 10 Gy, an enhanced green fluorescent protein reporter driven by the IFN-β1 promoter showed increased activity specifically in cells with micronuclei [10] .
Both cytosolic dsDNA and micronuclear DNA are likely to be important in driving acute IFN production and the subsequent antitumour inflammatory response following radiation. A substantial body of evidence from immunocompetent murine models indicates that the combination of radiotherapy plus immune checkpoint blockade (ICB) with anti-CTLA4 [11] , anti-PD-1 [12] or both [13] , can enhance both direct and abscopal responses to radiotherapy. Acute induction of the STING pathway is of particular importance for the abscopal response and both tumour-intrinsic and exosomal-mediated mechanisms of acute IFN production probably contribute to this effect ( Figure 1) .
Recent work has shed light on important associations between the presence of micronuclei and chromosomal instability (CIN) in the form of chromothripsis [14] . However, the precise mechanism of cell death in cells with micronuclei remains unclear and is likely to have important immunological consequences beyond the IFN responses discussed above. Apoptotic cell death, mitotic catastrophe or a combination of both may occur in irradiated cells with micronuclei [15] . Historically, apoptosis has been considered to have predominantly anti-inflammatory consequences. More recently, the phagocytic clearance of apoptotic cells by efferocytosis has been shown to increase immunosuppressive cytokines and leukocytes [16] . However, these anti-inflammatory effects are probably counterbalanced by the highly proinflammatory pre-apoptotic fragmentation and sensing of dsDNA [17] .
Optimising acute induction of type 1 IFNs in a therapeutic context
Optimising fraction size and total dose of radiotherapy
Optimal acute induction of type 1 IFNs is dependent on both the fraction size and the total dose of radiation [11] . In a series of experiments using TSA1 and MCA38 breast and colorectal mouse tumour models, respectively, the combination of radiotherapy, dosed at 24 Gy in three fractions or 30 Gy in five fractions, plus CTLA4 blockade, yielded antitumour responses in both the directly irradiated tumour and a second non-irradiated tumour on the contralateral flank (i.e. an abscopal response). However, the abscopal response was lost when a single ablative dose of 20 Gy was applied in combination with CTLA4 blockade.
The mechanistic basis of such radiation dose-dependent abscopal responses centres on induction of the cytoplasmic DNA exonuclease, Trex1, which degrades cytosolic dsDNA. Activation of Trex1 is thought to occur when supra-threshold levels of cytosolic dsDNA are reached [8] . In the above murine models, a short-lived but substantial induction of Trex1 was seen after a single 20 Gy fraction, but not after the other fractionation schedules, and this dose schedule was associated with attenuation of the type 1 IFN response. The additional relevance of the total dose of radiation was also shown experimentally; here, 24 Gy in three fractions generated much stronger abscopal responses than 8 Gy in a single fraction [8] . As yet, these intriguing preclinical findings on fraction size and total dose await human validation. Nevertheless, a large number of translational clinical trials, encompassing different fraction sizes and ICB, are underway, which should help to address this question [18] .
Addition of DNA damage response inhibitors (DDRi) to enhance the immunogenicity of radiation Addition of specific DDRi to radiotherapy may increase cytosolic DNA and thereby augment the IFN responses described above. AZD6738 is an ATR inhibitor (ATRi) that has shown radiosensitising effects preclinically [19] . It is currently being evaluated in early phase clinical trials, including the PATRIOT study (NCT02223923), which includes an arm in which AZD6738 is combined with palliative radiation [20] . AZD6738 has been evaluated in combination with radiotherapy in mouse models of K-ras mutant cancer. Here, the ATRi reduced radiation-induced surface expression of PD-L1 on tumour cells and also significantly reduced tumour infiltration of regulatory T cells. Enhanced antitumour CD8+ activity was seen as a result of these effects [21] .
Further evaluation of AZD6738 in an immunocompetent mouse model of HPV-driven malignancy also showed that AZD6738 potentiated radiation-induced inflammatory changes in the tumour microenvironment [22] . An increase in pattern recognition receptors sensing cytoplasmic nucleic acid and ISGs was seen with the addition of ATRi to radiotherapy, compared with radiotherapy alone. Further transcript-level data indicated increased antigen processing and presentation with ATRi plus radiotherapy versus radiotherapy alone. The combination of radiotherapy and ATRi also enhanced the intratumoural myeloid cell infiltrate. Although this myeloid infiltrate included a mixture of immunostimulatory and immunosuppressive cell populations, this study indicates the therapeutic potential of combining radiotherapy with DDRi and established or novel immunomodulatory agents.
The above data indicate considerable potential for DDRi, particularly ATRi, plus radiation to augment the type 1 IFN response to radiation. It will be exciting to see whether other DDRi, for example poly-ADP ribose polymerase (PARP) inhibitors, increase quantities of cytosolic DNA and thereby augment the downstream IFN response.
Novel immunomodulatory agents in combination with radiotherapy
Immunological consequences of RIDD 609 CCR2 is a receptor for monocyte chemoattractant proteins 1, 3 and 5 (CCL2, CCL7 and CCL12, respectively) and is expressed on the surface of a subset of monocytic myeloid-derived suppressor cells (mMDSCs). These CCR2 + Ly6C hi mMDSC cells are important mediators of radioresistance via immunosuppressive effects, which include negative regulation of tumour-specific CD8+ T cell responses [24] . Liang et al [24] demonstrated that the murine anti-CCR2 monoclonal antibody MC-21, plus stereotactic radiotherapy given at a dose of 20 Gy, significantly improved tumour rejection and substantially increased the CD8+/CD4+FoxP3+ (Treg) ratio in MC38 colorectal and Lewis lung cancer murine models. Tumour rejection was augmented with further addition of the STING agonist cGAMP to anti-CCR2 and ablative radiotherapy.
Intriguingly, the above study also showed that innate DNA sensing via STING, and the subsequent type 1 IFN response discussed earlier, play a key role in the recruitment of mMDSCs. This demonstrates the complexities of type 1 IFN signalling in tumour immunology, as well as how the induction of STING can be a double-edged sword with opposing antitumour and protumour immunological consequences.
The differential effects of acute versus chronic IFN signalling
Acute induction of type 1 IFN to drive activation of dendritic cells and subsequent CD8+ T cell priming is central to the generation of antitumour immune responses. However, chronic IFN signalling present within tumours prior to any treatment can promote an entirely different tumour phenotype, in which IFN paradoxically has a predominantly immunosuppressive effect [25] (Figure 2 ). Benci et al [25] explored the mechanisms of PD-L1-independent resistance to radiotherapy plus anti-CTLA4 in murine melanoma models. Here, chronic type I and II IFN production led to a multitude of STAT1-driven epigenetic and transcriptomic modifications. The consequences of such modifications included induction of multiple T cell inhibitor receptor (TCIR) ligands, including PD-L1, TNFRSF14, LGALS9, MHCII and CD86, as well as T cell exhaustion. Inhibition of IFN signalling by knockout of IFNAR, IFN-γR or STAT1, or use of the JAK1/2 inhibitor ruxolitinib, plus dual ICB inhibition, led to expansion and re-invigoration of distinct populations of exhausted T cells. The specific population showing most expansion was PD-1 high TCIR high T cells, which also showed an increase in markers of improved function, including Ki67 and Granzyme B [25] .
Both of the ISGs, IFIT1 and Mx1, showed a tight association with increased STAT1 expression. To demonstrate the clinical relevance of chronic IFN signalling, the expression of both genes was analysed in a recently published cohort of melanoma patients receiving PD-1 inhibition [25] . The computational modelling strategy incorporated ISG expression and the rates of non-synonymous single nucleotide variations, to account for the known effect of varying neoantigen load. The key findings were that lower IFIT1 and Mx1 expression and higher rates of non-synonymous single nucleotide variations correlated with increased response to treatment with anti-PD-1.
The precise relevance of such chronic IFN signalling to radioresponsiveness is not entirely clear. A substantial body of evidence indicates that upregulation of ISGs in tumours predicts a radioresistant phenotype. An experimentally derived IFN-related DNA damage resistance signature (IRDS), including STAT1, ISG15 and IFIT1, was developed by repeated irradiation to a xenograft of the radiosensitive cell line SCC-61 to generate a radioresistant tumour [26] . The resulting ISG-enriched signature [27] has subsequently been evaluated in different in vitro cell systems and xenograft models. Upregulation of IRDS genes has consistently been demonstrated during fractionated radiotherapy [28, 29] and constitutive expression of STAT1 and other ISGs has repeatedly predicted radioresistance [30] . In patients, analysis of gene expression databases has shown constitutive expression of ISGs in a substantial proportion of patients with head and neck, prostate, breast, lung and cervical cancers and high-grade gliomas [31] [32] [33] [34] . In breast cancer, an IRDS-based seven-gene classifier, including STAT1, was evaluated in 295 patients treated with adjuvant radiotherapy [27] . Patients with high expression of the signature (IRDS+) showed a significantly greater rate of locoregional failure at 10 years postradiotherapy.
Collectively, these studies indicate that constitutive STAT1/IFN signalling drives aggressive and radioresistant tumour phenotypes. Measurement of ISGs, such as Mx1 and IFIT1, may help to identify such phenotypes [25] . It is clear that the impact of chronic IFN signalling in driving unfavourable tumour biology is substantial (Figure 2 ). However, it is much less clear how tumours driven by chronic immunosuppressive IFN production can be manipulated to enable the beneficial antitumour effects of acute IFN induction during radiotherapy to predominate.
The role of stromal fibroblasts in chronic IFN signalling
A multifaceted heterotypic interaction between cancer-associated fibroblasts (CAFs) and tumour cells has been elucidated in recent years ( Figure 3 ). This complex interaction provides a mechanistic explanation for some of the aggressive tumour behaviour associated with upregulation of ISGs discussed above. A key aspect of the heterotypic interaction is the exosomal transfer of double-stranded RNA (dsRNA) from CAFs to tumour cells, where it binds the pattern recognition receptor been identified as the long non-coding RNA, RN7SL1 [36] . RN7SL1 exists endogenously in the cytosol, yet it is upregulated and unshielded in exosomes by an extensive transcriptional programme in CAFs, including NOTCH1 and MYC pathway signalling.
If breast cancer cells are separated from CAFs by a transwell filter, which enables exosomal transfer but does not permit cell-to-cell contact, upregulation of tumour cell ISGs is seen, but the radioresistance observed in ISG-high tumours does not occur [35] . This lack of radioresistance, despite paracrine signalling via exosomal dsRNA as described above, can be explained by further juxtacrine signalling in which NOTCH3 in breast cancer cells binds JAG1 on CAFs via direct cell-to-cell contact. The juxtacrine signalling drives an expansion of treatment-resistant CD44 + CD24 low+ cells with tumour-initiating properties. The paracrine and juxtacrine pathways ultimately converge because STAT1 enhances the transcriptional response to increased NOTCH3 signalling [35] . The stromal fibroblasts or CAFs, therefore, drive both reduced tumour cell death and increased tumour growth.
Boelens et al [35] carried out extensive expression profiling of human breast tumours as clinical qualification of the mechanisms identified in experimental models. Among other findings, they showed that breast tumour NOTCH3 and stromal JAG1 are important regulators of NOTCH target genes, and that NOTCH3 and STAT1 localise to sites of tumour-stroma interaction. Additionally, high IRDS/STAT1 and NOTCH3 identify patients with radio-and chemoresistance -this gene expression pattern is particularly common in basal and claudin-low subtypes of breast cancer, which are known to be enriched when cancer stem cell-like features are present. Both NOTCH3 and the IRDS (including STAT1) may prove to be useful predictive biomarkers to guide treatment with agents that block NOTCH activation, such as gamma secretase inhibitors [35] .
The importance of myeloid cell populations in the response to radiotherapy
Myeloid populations, e.g. tumour-associated macrophages (TAMs), are often abundant in the tumour microenvironment and are an attractive target for anticancer therapies, including combinations of radiotherapy and systemic agents [37] [38] [39] . Macrophages display significant plasticity, but are ordinarily classified between classically activated (M1) and alternatively activated macrophages (M2). Response to numerous inflammatory stimuli dictates the polarisation of macrophages towards M1 or M2 phenotypes [40, 41] . M1 macrophages are endowed with antitumoural activities and act mainly as a driver of a protective T H 1 immune response, whereas M2 macrophages are responsible for tumour growth and resistance to anticancer therapies [42] .
In tumours, macrophages usually possess a deleterious M2 phenotype, which promotes angiogenesis, suppression of antitumour T cell responses and metastatic dissemination. Consequently, high numbers of TAMs are generally associated with poor prognosis and lower survival rates in cancer patients [43, 44] . Several reports have demonstrated an increase in macrophage infiltration in tumours following radiotherapy, which may limit treatment efficacy. However, studies of polarisation of recruited TAMs following radiotherapy have yielded conflicting results, depending on the tumour model, radiation fraction size and total dose, and the host's genetic background [45] .
The RIDD response pathway is likely to be important for the activation of macrophages towards a proinflammatory M1-like phenotype [46] . Wu et al showed that NOX2-dependent reactive oxygen species production following radiotherapy induced ATM phosphorylation, which subsequently led to IRF5 expression and proinflammatory responses in macrophages. These data suggest that systemic agents that modulate the RIDD response may favourably influence macrophage function to improve antitumour responses, as well as enhancing the postradiotherapy acute type 1 IFN response discussed earlier.
The molecular mechanisms regulating macrophage infiltration and activation following radiotherapy in tumours have been extensively investigated. Findings indicate that there is potential for therapeutically beneficial immune modulation using agents that may synergise with DDRi. In a xenograft model of non-small cell lung carcinoma, IL-6 induced the recruitment of macrophages in irradiated tumours via CCL2/CCL5 secretion [47] . Colony-stimulating factor-1 was also proposed as an important factor in recruiting macrophages in mouse mammary tumours [48] . In addition, neutralisation of cytokines that are important for M2 polarisation (IL-4 and IL-13) enabled the reduction of tumour growth. Tumours originating from the 4T1 breast cancer cell line show higher proportions of iNOS + TAMs (M1) following inhibition of MMP14 [49] . M1 macrophage recruitment, together with a reduction of anti-inflammatory TGF-β, improved radiotherapy-mediated tumour control.
More research is required to understand fully the molecular determinants of TAM polarisation following radiotherapy and to optimise drug combinations to exploit the potential of macrophage reprogramming postradiotherapy. Possible synergistic drug combinations include DDRi in combination with other immunomodulatory agents. Such combinations may enable both the suppression of deleterious macrophages and the promotion of beneficial antitumour macrophages following radiotherapy.
How do immunogenic properties of radiotherapy established in preclinical models apply in a human context?
Key differences between human tumours and murine model systems
The mechanistic studies explained above are, by necessity, conducted in experimental murine models and it is unclear how these findings translate into a human context. The radiotherapy schedules used in the above studies are reasonably representative of schedules used in the clinic. However, there are important biological differences between primary and secondary human tumours and the above model systems. The time period over which branched evolution operates within human tumours does not apply to murine models. This means that intratumoural genomic heterogeneity is probably much greater in human tumours than in commonly used murine models. Furthermore, the biological mechanisms enabling successful metastasis of human tumours do not occur in the bilateral flank models typically used to evaluate the abscopal response in murine tumour systems. As a consequence, the genetic and phenotypic variation between human primary and metastatic tumours is probably considerably greater than in the equivalent murine models.
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Chromosomal instability
Human tumours are likely to exhibit a greater degree of CIN than their murine equivalents and CIN is thought to occur to a larger extent in metastases than in primary tumours [50] . Recent data suggest that increased cytosolic DNA and cGAS/STING signalling occur in untreated cancer cells with high CIN, and such signalling is involved in metastatic progression. Cancer cells with high CIN, and those isolated from metastases, have higher numbers of micronuclei and greater quantities of cytosolic DNA than primary tumours with low CIN. Additionally, if micronuclear envelope incompetence is suppressed, quantities of cytosolic DNA are reduced in high CIN cells. The increased cytosolic DNA in high CIN cells can activate non-canonical NF-κB signalling in a STING-dependent, yet MYCand TBK1-independent, manner. Such signalling can be important for metastatic progression, as tumour dissemination was reduced in models of high CIN depleted of STING [50] . This diversion away from a STING-dependent inflammatory response towards non-canonical signalling in tumours with high CIN may impact how effectively an acute IFN response, and subsequent abscopal response, is generated following radiotherapy.
The DNA exonuclease Trex1, discussed earlier in the context of radiotherapy fraction sizes, also has a role in human chromothripsis. Chromothripsis, or chromosome shattering, is thought to occur as a single event during which a high number of focal copy number alterations are generated. Trex1 has a specific role in the resolution of anaphase bridges following telomere fusion, which is an important mechanism for chromothripsis [51] . This illustrates how key proteins linking the DDR and immune response have much wider roles, including the regulation of chromosomal stability. The cGAS/STING pathway is increasingly recognised to have diverse context-dependent components, and an improved understanding of the complexities of this pathway will be necessary for the development of successful human trials of immunotherapy/radiation combinations.
Generation of antitumour CD8+ T cell responses
Radiation-induced cell lysis causes release of tumour neoantigens that are taken up by antigen-presenting cells in the surrounding tumour microenvironment. The subsequent sustainment of an antitumour immune response probably requires generation of CD8+ T memory cells that recognise these tumour neoantigens [52] . A CD8+ T cell response to clonal neoantigens, rather than subclonal neoantigens, is thought to be important [53] . The considerable genomic diversity of human tumours may limit the effectiveness of CD8+ T cell responses following irradiation of a single site, with failure to engage neoantigens that are private to other non-irradiated tumour sites. However, it is also possible that 'epitope spreading' occurs in which a strong response to one epitope supports the generation of responses to other less immunogenic neoepitopes [54] . It has been suggested that radiotherapy may increase subclonal neoantigens, potentially leading to T cell exhaustion [53] . However, to our knowledge this has not been shown to date, in either experimental models or patients receiving radiotherapy.
The evolution of T cell receptor (TCR) clones during radiotherapy, in both human and murine models, is a particularly exciting area of current research. In a study of radiotherapy combined with CTLA4 blockade in the 4T1 breast cancer mouse model, clonally expanded tumour-specific T cells formed the majority of the CD8+ T cell population [55] . Deep sequencing of TCR-β showed that radiotherapy broadened the TCR repertoire, as has also been reported in other murine tumour models [12, 13] . In contrast, anti-CTLA4 treatment increased TCR clonality and, therefore, focused the TCR repertoire. These TCR dynamics, driven by radiation-induced inflammatory changes, may be important for the observed tumour rejection in these models.
Early findings from a human trial of radiotherapy plus ipilimumab in patients with non-small cell lung cancer also show a diversification and intensification of TCR clones during radiotherapy [56] . In this study, the persistent expansion of tumour-specific T cell clones in peripheral blood correlated with a partial or a complete response to treatment. A particularly interesting finding was seen in a patient showing a complete response to radiation and ipilimumab. Here, expansion of two tumour-specific T cell clones recognising epitopes within the gene KPNA2 was seen. KPNA2 is known to be upregulated by radiotherapy. Importantly, an increase in serum IFN-β from baseline was significantly correlated with a radiological response to radiotherapy plus ipilimumab. Together, these findings suggest that radiation may reveal immunogenic mutations by increasing their expression, thus enabling antigen presentation, production of IFN-β and a subsequent T cell response. These exciting early findings require confirmation in other larger patient cohorts, together with much more research, to understand how radiotherapy plus immunomodulatory combinations impact T cell clonal evolution in human tumours.
Conclusion
There is a wealth of preclinical data indicating that RIDD and the immune response can be exploited for therapeutic benefit. Radiotherapy and immunotherapy as an effective combination has already been demonstrated in the randomised placebo-controlled phase III PACIFIC trial of the PD-L1 inhibitor durvalumab after chemoradiotherapy in locally advanced lung cancer [57] . Here, the added overall benefit in terms of median time to death or distant metastases of the addition of durvalumab was just over 12 months [58] . ThereImmunological consequences of RIDD 613 about the relationship between radiotherapy and the immune response, particularly in a human context. Currently, there is an urgent need for high-quality human studies with translational endpoints that profile longitudinal changes occurring during radiotherapy alone, and with radiation and ICB (or other immunomodulatory treatments, including chemotherapy) combinations. Such studies ideally need to incorporate measures of CIN, stromal fibroblast biology and IFN signalling at baseline, and during radiotherapy. These translational studies should further our understanding of the evolution of tumours, their associated microenvironments and TCR clones during radiotherapy, paving the way for therapeutic gains for patients.
